A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network.
Carrie M HershZhaonan SunDevon S ConwayElias S SotirchosKathryn C FitzgeraldLe H HuaTjalf ZiemssenRobert T NaismithFabio PellegriniCynthia GrossmanNolan CampbellPublished in: Multiple sclerosis and related disorders (2024)
The relative benefit of selecting higher efficacy treatments may vary depending on patients' baseline brain atrophy risk. Poor outcomes are predicted in individuals with high baseline risk who are treated with low-efficacy DMTs.
Keyphrases
- multiple sclerosis
- white matter
- end stage renal disease
- newly diagnosed
- resting state
- ejection fraction
- chronic kidney disease
- mass spectrometry
- peritoneal dialysis
- prognostic factors
- ms ms
- functional connectivity
- type diabetes
- metabolic syndrome
- insulin resistance
- brain injury
- skeletal muscle
- replacement therapy
- breast cancer risk